Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. - Wikidata - awgldk - TriplyDB

Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide.

Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide.

http://www.wikidata.org/entity/Q39341524

about

Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma Treatment of relapsed and refractory multiple myeloma Monoclonal antibodies targeting CD38 in hematological malignancies and beyond Selection and expansion of natural killer cells for NK cell-based immunotherapy Human NK Cell Subsets Redistribution in Pathological Conditions: A Role for CCR7 Receptor Mechanisms of action of therapeutic antibodies for cancer Daratumumab: First Global Approval.A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma.Therapeutic potential and challenges of natural killer cells in treatment of solid tumors Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions.Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia-Microenvironment Interactions in Chronic Lymphocytic Leukemia.The safety of daratumumab for the treatment of multiple myeloma.Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab.New developments in the treatment of multiple myeloma - clinical utility of daratumumab.Immunotherapies targeting CD38 in Multiple Myeloma.Safety issues and management of toxicities associated with new treatments for multiple myeloma.Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progression Modeling Natural Killer Cell Targeted Immunotherapies.Natural Killer Cell Response to Chemotherapy-Stressed Cancer Cells: Role in Tumor Immunosurveillance.Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia (T-ALL).Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab.Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs.Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering.Antibody based immunotherapy for multiple myeloma: it's about time.Tumor immunotherapy: New aspects of natural killer cells.Next generation immune-checkpoints for cancer therapy.CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients

P2860

Q26745919-5D97409C-31EC-4C19-82FA-638B1ACB7DE6 Q26749180-B5AA4918-54CC-4D15-B1C5-75F9A69A26BE Q26766718-0CD85D77-C050-4163-B06C-A8D49B1D9D4F Q26774777-CBC10A29-6726-4C1E-86AB-DFD3100AFFD7 Q28067468-919617A1-DB5A-4AAE-BC94-8DE3561BF86F Q28385366-EC999762-C90E-47C4-AFF5-BD8F399956AB Q34507354-E22CE418-3A75-451D-8669-68742E6934F4 Q36070261-79560B86-3331-4438-9D0E-68AD3D70612C Q38478878-94F85B1A-7A03-4918-831B-1ED4DDA6573C Q38542034-37B67B0D-83ED-4609-9E13-3F337533DBD4 Q38737970-9782CE15-19DB-4E08-B00F-A4E5049529AF Q38745915-BA7A25ED-F0E6-4807-AF7E-1169418EE06A Q38793959-679AA167-5473-4CDC-BC58-E274FC94B901 Q38809499-0254200B-7677-4239-BF73-D2153F0B88BD Q38820002-62B8CF9F-E53E-4595-9BB6-FD74E4940BF3 Q39045031-5CE48D69-DB72-4F1C-9F61-B81DC1EEE3ED Q39100317-BD9BFD57-1F19-4D0A-8883-9F206FEDDADE Q39136762-50311412-2FE6-4D7C-A6F3-F2E50D336AED Q39239278-B702B2E8-9740-48FA-AD5D-18956CF6E4EE Q42042886-423C5449-7080-441E-998C-DDF74A9ADBB2 Q47203479-27AF1F56-9730-42DF-8307-1E7FBF4F12CB Q47660573-3A7B65DD-4C69-486C-9BF4-D31025B53484 Q49830211-5AC1049B-B6D1-41C4-B9EF-C85A6DD4E931 Q52615722-1BF60C1B-9E98-4F1C-8A3D-DC03399F349E Q53349911-9A3F8BAA-73A1-4F50-B3DB-15719C54A65E Q55107050-B98A15AF-BE56-448F-97EB-4B7C1F82FBBE Q55383705-695ED371-1925-4F81-B0F0-0E768E100123 Q57191729-A5EADF4C-5A85-4EDC-A555-651C5998C58A Q58552961-05E01679-3D83-4056-A235-35C76FABC12C

P2860

Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide.

http://www.wikidata.org/entity/Q39341524

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Daratumumab-mediated lysis of ...... body IPH2102 and lenalidomide.

@en

Daratumumab-mediated lysis of ...... body IPH2102 and lenalidomide.

@nl

type

label

Daratumumab-mediated lysis of ...... body IPH2102 and lenalidomide.

@en

Daratumumab-mediated lysis of ...... body IPH2102 and lenalidomide.

@nl

prefLabel

Daratumumab-mediated lysis of ...... body IPH2102 and lenalidomide.

@en

Daratumumab-mediated lysis of ...... body IPH2102 and lenalidomide.

@nl

P1433

Q39341524-90286517-088F-4CA7-875D-3BA4C17FB8BE

P1476

Q39341524-183E1137-C0A6-46BD-979E-CC4175E22CA0

P2093

Q39341524-156AE1EB-06E4-43B0-A60D-BEF4BBBEC917

Q39341524-45EBB82A-4B5C-4E4A-AF54-63152F830BD5

Q39341524-5253AFB2-6267-40B3-B354-E9EC9B7A470D

Q39341524-73C0A238-FC37-4931-995F-38E50D244294

Q39341524-990E477B-7907-48BD-9A2D-8F65AE711ADA

Q39341524-B4B7FE19-77AA-4F00-8F8C-E71487E6DD87

Q39341524-BA6D2FCE-AE5E-43E0-AF1D-3B7FEF346211

Q39341524-E4BBF3E5-E11F-41F1-BAB8-E1079466FDAF

P2860

Q39341524-00401AE4-3EF3-40C3-A3C6-E1DDE55942F3

Q39341524-0F4EE783-46EB-4F66-ABE7-BA5385FDF00C

Q39341524-12B610A4-82B7-4BA6-A91C-54D866F7EC98

Q39341524-232E3165-021F-442C-B55F-E45646EC328C

Q39341524-23B55F67-F96B-4734-9443-AF83E7D7D3FB

Q39341524-2A5C3287-2FED-4791-B944-08FBD3E1145A

Q39341524-2F5EE34A-620A-4D75-AA7C-8DE2A5C3DD06

Q39341524-3D257F90-C53C-4829-B78B-DD48AA51A465

Q39341524-4ADE78A7-7E50-4A8A-AE39-618C6DF45ED3

Q39341524-4F0A5613-8B84-4228-99D9-7F1E10249BC6

P304

Q39341524-2E938568-C3F2-499D-9880-969E3F2D6007

P31

Q39341524-6F31C97E-CA85-46D3-86C8-3350FB59ECD9

P356

Q39341524-A60FF25B-A70A-4641-B503-6691166954CD

P433

Q39341524-01222638-92BC-452B-9CFB-13856565C604

P478

Q39341524-3CCCD9F8-27D7-4325-9D98-72BD0BA03DD2

P50

Q39341524-F0AD965D-0623-4D05-A89C-EF7567A1D862

P577

Q39341524-2EC58FF9-99FF-48E5-8234-B76BB1543B65

P698

Q39341524-EFABBCF3-0DBF-4A4D-B786-76B89DE6F2C5

P921

Q39341524-C43446DA-F644-486F-A9CB-C09E83B0C128

P932

Q39341524-4354F0A1-E355-4048-A015-DCDDE927E4C2

P356

HAEMATOL.2014.117531

P1433

P1476

Daratumumab-mediated lysis of ...... body IPH2102 and lenalidomide.

@en

P2093

Berris van Kessel

http://www.w3.org/2001/XMLSchema#string

Henk M Lokhorst

http://www.w3.org/2001/XMLSchema#string

Inger S Nijhof

http://www.w3.org/2001/XMLSchema#string

Jeroen J Lammerts van Bueren

http://www.w3.org/2001/XMLSchema#string

Niels W C J van de Donk

http://www.w3.org/2001/XMLSchema#string

Pascale Andre

http://www.w3.org/2001/XMLSchema#string

Tuna Mutis

http://www.w3.org/2001/XMLSchema#string

Yannis Morel

http://www.w3.org/2001/XMLSchema#string

P2860

Functions of natural killer cells

NK cell recognition

Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells.

Lenalidomide for the treatment of relapsed and refractory multiple myeloma.

Variant genotypes of the low-affinity Fcgamma receptors in two control populations and a review of low-affinity Fcgamma receptor polymorphisms in control and disease populations.

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study.

Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.

Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype.

FcgammaR polymorphisms: Implications for function, disease susceptibility and immunotherapy.

A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma

P304

263-268

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3324/HAEMATOL.2014.117531

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

100

http://www.w3.org/2001/XMLSchema#string

P50

Paul Whi Parren

P577

2014-12-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25510242

http://www.w3.org/2001/XMLSchema#string

P921

P932

4803142

http://www.w3.org/2001/XMLSchema#string